|
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for …
PR Newswire (press release) Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. … |
View full post on asthma – Google News